Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower second-quarter results due to persistently weak demand for its Gardasil vaccine in ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

The Gardasil human papillomavirus virus vaccine remains Merck’s second best-selling drug behind cancer treatment Keytruda. Global Gardasil sales fell 55 per cent in the quarter to $1.1bn. Merck said ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck CFO Caroline Litchfield tried to reassure investors and said that "Gardasil China represents a fraction of our company now, much less than 1%, we're not counting on it for growth." ...